Schering-Plough's drug sugammadex for the reversal of general anesthesia was rejected by U.S. regulators.
They received a ``not-approvable'' letter from the Food and Drug Administration, the drugmaker said today in a statement. Schering-Plough said it would work with the agency to ``address the issues, which are primarily related to hypersensitivity/allergic reactions.''
More
No comments:
Post a Comment